Scinovex
articleTop 1% cited

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome

Movement Disorders · 2017 · Vol. 32(5) · pp. 739–749
Erin M. Hill‐BurnsJustine W. DebeliusJames T. MortonWilliam T. WissemannMatthew R. LewisZachary D. WallenShyamal D. PeddadaStewart A. FactorEric MolhoCyrus P. ZabetianRob KnightHaydeh Payami

Abstract

PD is accompanied by dysbiosis of gut microbiome. Results coalesce divergent findings of prior studies, reveal altered abundance of several taxa, nominate functional pathways, and demonstrate independent effects of PD medications on the microbiome. The findings provide new leads and testable hypotheses on the pathophysiology and treatment of PD. © 2017 International Parkinson and Movement Disorder Society.

Gut microbiota and healthDiet and metabolism studiesDysphagia Assessment and ManagementParkinson's diseaseDiseaseMicrobiomeGut microbiomeMedicineNeurosciencePsychologyBiologyBioinformaticsPathology

MeSH terms

Gastrointestinal MicrobiomeAge FactorsAntiparkinson AgentsBifidobacteriumCarbidopaDietDrug CombinationsFemaleFruitHumansLactobacillaceaeLevodopaMaleParkinson DiseaseRisk Factors

Funding

  • National Institute of Neurological Disorders and Stroke
Citations
864
FWCI
28.10
field-weighted impact
References
58
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.